TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00703820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: See Detailed Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: See Detailed Description

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study: NCT03380611

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wakame
Description: Consumption of 4.8 grams wakame per day for 17 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Consumption of 4.8 grams spirulina per day for 17 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Consumption of microcrystalline cellulose for 17 days
Study: NCT01404598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 bid
Description: naproxcinod 750 bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 3000 mg od
Description: naproxcinod 3000 mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 500 mg bid
Description: naproxen 500 mg bid
Study: NCT02621086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellodextrin
Description: Gastrointestinal tolerability of single ascending doses of Cellodextrins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellodextrin
Description: Gastrointestinal tolerability of single ascending doses of Cellodextrins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellodextrin
Description: Gastrointestinal tolerability of single ascending doses of Cellodextrins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellodextrin
Description: Gastrointestinal tolerability of single ascending doses of Cellodextrins
Study: NCT03639896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
Study: NCT03172234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral amantadine sulfate
Description: In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral gabapentin
Description: In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
Study: NCT01522573

Intervention type: PROCEDURE
Intervention: EUS guided ERCP
Description: Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
Study: NCT01176708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose
Description: 50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose
Description: 50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose
Description: 50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous glucose
Description: 1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
Study: NCT01785108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Study: NCT00228943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Description: L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Half-strength tryptophan depletion (Control)
Description: L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
Study: NCT01176708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous glucose
Description: 1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous glucose
Description: 1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
Study: NCT01597466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural catheter placement
Description: Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter placement
Description: Epidural space is located using loss of resistance technique (saline solution)
Study: NCT01020344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung volume reduction surgery
Description: Lung volume reduction surgery
Study: NCT02427035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% weight/volume sodium chloride solution (ie, normal saline)
Study: NCT01730352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori triple therapy
Description: Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
Study: NCT02427035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% weight/volume sodium chloride solution (ie, normal saline)
Study: NCT02448706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Fitting A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Fitting A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Fitting B

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Fitting B
Study: NCT00658827

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
Study: NCT01139541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social walking intervention
Description: In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social walking intervention
Description: In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social walking intervention
Description: In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
Study: NCT02353858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep regional hyperthermia
Description: Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-Fluorouracil)
Description: 5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
Study: NCT04684940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Study: NCT00566046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
Study: NCT00938912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day.
Study: NCT02420184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No CPAP
Description: Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
Study: NCT02076529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron 0.3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.45mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6mg
Study: NCT03322631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT02614339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
Study: NCT03625089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Group 1 patients will be prescribed statin when FRS \> 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS\>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Group 1 patients will be prescribed statin when FRS \> 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS\>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom.
Study: NCT00225212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2
Study: NCT00683007

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume resuscitation (Crystalloid)
Description: Crystalloid vs. Hypertonic Saline Solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume resuscitation (Hypertonic Saline Solution)
Description: Crystalloid vs. Hypertonic Saline Solution
Study: NCT01463657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm® Ultra Plus
Description: Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002
Description: Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
Study: NCT03584438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study: NCT00100646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Description: Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
Study: NCT00100646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 300 mg tablet taken orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 300 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
Study: NCT00658827

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
Study: NCT00140426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
Study: NCT00100646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage dependent on weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Dosage dependent on weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies de novo antigen
Description: Vaccine injected intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies de novo antigen
Description: Vaccine injected intramuscularly
Study: NCT01604096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted information campaign
Description: Following is the description of the multifaceted intervention:~* brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~* posters (same distribution as brochures)~* short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~* radio-spots transmitted in local radio stations~* advertisements in local newspapers~* banners on websites of local newspapers~* newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~* training courses in counselling strategies, directed to a subgroup of GPs and paediatricians
Study: NCT01674127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02126813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: increased interventional threshold for urinary bladder catheterization (800 ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current used interventional threshold for urinary bladder catheterization (500 ml)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bladder catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheter
Study: NCT00985712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huminsulin Regular
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huminsulin Regular
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HumaPen Memoir
Description: subcutaneously, daily for 24 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HumaPen Luxura
Description: subcutaneously, daily for 24 weeks
Study: NCT04054960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tPCS
Description: Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tPCS
Description: For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
Study: NCT02464020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral vancomycin: 500mg suspended in prefilled syringes for oral use
Study: NCT01959074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftopidil
Description: Naftopidil 75mg 1T qd hs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Naftopidil
Description: Placebo 1T qd hs